Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab

U Disel; S Paydas; S Yavuz; E Karakoc

doi:10.1159/000305255

Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab

Chemotherapy. 2010;56(2):89-93. doi: 10.1159/000305255. Epub 2010 Mar 30.

Authors

U Disel¹, S Paydas, S Yavuz, E Karakoc

Affiliation

¹ Department of Oncology and Intensive Care Unit, Cukurova University Faculty of Medicine, Adana, Turkey.

PMID: 20357439
DOI: 10.1159/000305255

Abstract

Fludarabine is a nucleoside analogue used in the treatment of low-grade lymphoproliferative disorders and in conditioning regimens of non-myeloablative allogeneic stem cell transplantation. This is a relatively safe drug for clinical use but may cause side effects, some of which may be life-threatening. Here a case of severe pulmonary toxicity associated with fludarabine and a possible contribution of rituximab is presented and the literature reviewed.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lung Diseases / chemically induced*
Lung Diseases / physiopathology
Lymphoma, Follicular / drug therapy
Male
Middle Aged
Rituximab
Severity of Illness Index
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Rituximab
Vidarabine
fludarabine